(redirected from Trasylol)
Also found in: Medical.


 (ā-prōt′n-ĭn, ă-prōt′-)
A polypeptide obtained from bovine lungs that is a protease inhibitor and has been used to reduce bleeding in patients undergoing cardiopulmonary bypass surgery. It was largely withdrawn from the market in 2007 because of safety concerns.

[a- + prot(e)in(ase) + -in.]
References in periodicals archive ?
July 21, 2009) (stating that expert testified that the Hill criteria are generally accepted); In re Trasylol Prods.
The Inhibition of Trasylol of Fibrinolytic Activity Associated with Cardiovascular Operations.
Drugs that have reached the market with no listed patents, but only regulatory exclusivity, include: Mefloquine HCl (mefloquine hydrochloride), Clozaril (clozapine), Hexalen (altretamine), Leustatin (cladribine), Trasylol (aprotinin bovine), Sclerosol (talc), and Ellence (epirubicin hydrochloride).
For instance, in the Trasylol MDL, centralized in Florida, the defendant was a Pennsylvania corporation with its principal place of business in Indiana.
2001) evaluaron la inmovilizacion de condrocitos empleando geles de fibrina y alginato de sodio polimerizados con cloruro de calcio y trombina; una vez inmovilizadas las celulas, las cultivaron en frascos Roller usando medio de cultivo DMEM/Ham's F-12 con suero bovino al 10% y Trasylol (aprotinina, Laboratorio Bayer), como resultado obtuvieron el crecimiento celular de condrocitos y el mantenimiento de esta linea celular por el uso de alginato de sodio.
Trasylol was acquired from Bayer (Germany), tissue-type plasminogen activator (tPA) from American Diagnostica (Greenwich, Connecticut, USA) and soya lecithin from Now Natural Foods (Bloomingdale, Illinois, USA).
1 g/1 NaHCO3, 1% minimal essential vitamins and 20,000 kIE/1 trasylol in a humidified atmosphere of 5% [CO.
The Food and Drug Administration learned of the trial and issued a public health advisory stating that "[the] use of Trasylol may increase the chance for death, serious kidney damage, congestive heart failure and strokes.
In preclinical testing, Textilinin has compared favourably to other antifibrinolytic products such as Trasylol (aprotinin), a product used to reduce perioperative blood loss in patients undergoing coronary artery bypass graft surgery (CABG).
In 2008, cancer drug Nexavar achieved 76% growth, offsetting the drop in hematology/cardiology sales (-13%), impacted by the suspension of Trasylol back in November 2007.
They cite the withdrawal of Vioxx, Trasylol, fen-phen, and Redux from the market as examples of the pharmaceutical industry's failure to adequately warn consumers of drug hazards even when the manufacturers knew of the risks.
Among them were Zelnorm, Exubera, Trasylol, Pergolide and Premax--none of them blockbusters for sure, but all with significant sales and more significant potential had they proven safe and effective post approval.